Condition: Coronary Artery Disease · Heart Failure · Sponsor: Vastra Gotaland Region
The primary objective of the STICH 3.0 Study is to determine whether CABG is superior to PCI in terms of all-cause mortality at 5 years in patients with severe CAD and iLVSD. Individual patient data from similar national RCTs independently powered for different efficacy endpoints will be pooled, harmonized, and analyzed. The primary endpoint is all-cause mortality.
This description comes directly from the study's public registry record.
Björn Redfors, MD, PhD · +46 313421000 · bjorn.redfors@wlab.gu.se
Mark Petrie, MD, PhD, Professor · +44 141 330 4558 · Mark.Petrie@glasgow.ac.uk
Always discuss trial participation with your own doctor first.
| Dep of Cardiology, Sahlgrenska University Hospital | Gothenburg, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05761067